The purpose of this study is to evaluate pulmonary function of patients recovering from mild, moderate, and severe COVID-19 disease using hyperpolarized 129Xe MRI.
COVID-19, the disease at the heart of the current global pandemic, is characterized by
fevers, cough, sore throat, malaise, and myalgias, with 98% of patients experiencing some
pulmonary involvement. In those infected with the causative virus, SARS-CoV-2, the severity
of symptoms, as well as their duration, is widely variable. There is strong evidence from
computed tomography (CT) images of patients with severe COVID-19 that pulmonary abnormalities
and lung damage caused by infection may have long-term consequences for survivors.
Furthermore, many patients with mild or moderate experience symptoms such as fatigue and
dyspnea long (>60 days) after initial symptom onset, but there are currently no clinical
predictors of which patients are at greatest risk for long-term health effects. As such,
sensitive and specific predictors or biomarkers that can evaluate quality-of-life, risk of
infection exacerbation, and long-term outcomes are critically needed.
Pulmonary imaging using hyperpolarized (HP) 129Xe magnetic resonance imaging (MRI) provides a
means to detect abnormalities in the pulmonary small airways, vasculature, and parenchyma by
quantifying pulmonary ventilation, gas diffusion, and regional gas exchange. HP 129Xe MRI is
fast (<16s), non-invasive, and radiation free, making it a safe and effective method for
characterizing lung function, even in individuals with lung disease. In this pilot study, we
will use HP 129Xe to evaluate pulmonary structure and function in COVID-19 patients using the
following specific aims:
Aim 1. Detect regional pulmonary function abnormalities in recovering COVID-19 patients using
hyperpolarized 129Xe MRI. The hypothesis is that ventilation and gas exchange defects will be
present in recovering COVID-19 patients, and further that the extent of impairment will
correlate with disease severity.
Aim 2. Determine risk factors for long term outcomes using hyperpolarized 129Xe MRI and
clinical biomarkers. The hypothesis is that HP 129Xe MRI biomarkers will predict long-term
lung function impairment brought on by COVID-19.
These aims will be tested by performing HP 129Xe MRI in patients recovering from mild,
moderate, or severe COVID-19. By coming to a fuller understanding of the long-term impairment
of pulmonary function, future treatment can be optimized to minimize severe disease and
health care utilization.
Drug: Hyperpolarized Xe129
Subjects will inhale up to 4 doses of hyperpolarized Xenon gas in order to image pulmonary function.
Other Name: Array
Inclusion Criteria:
- Oxygenation saturation of ≥88% at rest by study staff within 48 hours prior to study
entry.
- The participant has a previous diagnosis of COVID-19 confirmed by COVID-19 PCR or
antibody testing and is being seen for outpatient follow-up.
- Subject is at least 10 days post-symptom-onset and do not have a fever (<99.5°).
- Ability to read and understand English or Spanish
Exclusion Criteria:
- Subject is less than 18 years old
- MRI is contraindicated based on responses to MRI screening questionnaire
- Subject is pregnant or lactating
- Subject does not fit into 129Xe vest coil used for MRI
- Subject cannot hold his/her breath for 15-16 seconds
- Subject deemed unlikely to be able to comply with instructions during imaging
- Oxygen saturation <88% on room air or with supplemental oxygen
- Cognitive deficits that preclude ability to provide consent
- Institutionalization
University of Kansas Medical Center
Kansas City, Kansas, United States
Investigator: Peter J Niedbalski, PhD
Contact: 913-588-2271
pniedbalskI@kumc.edu
Peter J Niedbalski, PhD
9135882271
pniedbalski@kumc.edu